What is already known about this topic?
Obesity is a well-known risk factor for development of renal cell carcinoma. However, the clinical importance of obesity and volumetric body composition parameters (VBC), visceral adipose tissue (VATI), subcutaneous adipose tissue index (SATI), in predicting survival outcomes of metastatic renal cell carcinoma (mRCC) treated with targeted therapy, sunitinib or pazopanib, remain to be elucidated. The present study aimed to investigate the prognostic value of both VBC parameters and skeletal muscle index, an indicator of sarcopenia, in mRCC patients treated with targeted therapy.